nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.02.2016 | Editorial

Note of clarification regarding data on the association between the interleukin-1β −511C>T polymorphism and breast cancer risk

verfasst von: Yadong Wang, Xinwei Chu, Haiyu Wang

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Excerpt

With great interest, we have read a recent article entitled “Three polymorphisms in interleukin-1beta gene and risk for breast cancer: a meta-analysis”, which was published online in Breast Cancer Research and Treatment [1]. In this article, Liu et al. conducted a meta-analysis to address the association between the interleukin-1β (IL-1β) gene −511C>T polymorphism and the risk of breast cancer [1]. Their results showed that the polymorphism of IL-1β −511C>T was not associated with the risk of breast cancer. It is an extremely valuable study. …

Liu X, Wang Z, Yu J, Lei G, Wang S (2010) Three polymorphisms in interleukin-1beta gene and risk for breast cancer: a meta-analysis. Breast Cancer Res Treat 124:821–825CrossRefPubMed

Smith KC, Bateman AC, Fussell HM, Howell WM (2004) Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31:167–173CrossRefPubMed

Liu J, Zhai X, Jin G, Hu Z, Wang S, Wang X, Qin J, Gao J, Ma H, Wei Q et al (2006) Functional variants in the promoter of interleukin-1beta are associated with an increased risk of breast cancer: a case-control analysis in a Chinese population. Int J Cancer 118:2554–2558CrossRefPubMed

Hefler LA et al (2005) Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women. Clin Cancer Res 11(16):5718–5721CrossRefPubMed

Balasubramanian SP et al (2006) Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 6(1):188PubMedCentralCrossRefPubMed

Pooja S et al (2012) Polymorphic variations in IL-1β, IL-6 and IL-10 genes, their circulating serum levels and breast cancer risk in Indian women. Cytokine 60(1):122–128CrossRefPubMed

Titel: Note of clarification regarding data on the association between the interleukin-1β −511C>T polymorphism and breast cancer risk
verfasst von: Yadong Wang
Xinwei Chu
Haiyu Wang
Publikationsdatum: 01.02.2016
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2016
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-3722-2

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Note of clarification regarding data on the association between the interleukin-1β −511C>T polymorphism and breast cancer risk

Excerpt

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Note of clarification regarding data about the association between the interleukin-1β −31T>C polymorphism and breast cancer risk

Erratum to: Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option

Healthy dietary patterns and risk of breast cancer by molecular subtype

Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor

Effect of a randomized controlled exercise trial on bone outcomes: influence of adjuvant endocrine therapy

Erratum to: CXCL13–CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie